Through the introduction of innovative medicines, Eton Pharmaceuticals Inc. (NASDAQ:ETON) has taken up the responsibility of advancing the healthcare sector. This is in addition to ensuring that the medicines are available and affordable to all patients. The company has accomplished yet another milestone, having submitted a new drug application (NDA) for dehydrated alcohol injection to the FDA.
The product, previously known as DS-100, is a potential treatment for methanol poisoning and will come in handy during these crazy times of COVID-19. Manufactures of hand sanitizers are using excessive methanol in their products; hence cases of methanol poisoning are anticipated to rise. The increasing misuse of methanol in the recent past has pushed the FDA to recall more than 75 different hand sanitizers from different manufactures.
The launch of the product soon
“We are very excited to add another orphan drug NDA submission to our late-stage pipeline,” said Eton Pharmaceuticals, Sean Brynjelsen. He pointed out his team’s effort, and the company’s partners had put into the extensive clinical and development activities of DS-100.
Additional good news is that the product already received orphan drug designation. This means it has a tag of seven years of market exclusivity once it is approved. The FDA has reported adverse events resulting from methanol poisoning, including blindness and hospitalization. However, Eton s hopeful of launching DS-100 in the new future, and this is expected to mitigate the suffering in hundreds of patients.
Improving the Lives of both the Patients and the Physicians
Superior and improved products are not only beneficial to patients but also patients. Eton has another seven products under development, including zonisamide oral suspension. Zonisamide is used to treat partial seizures, and Brynjelsen says the demand for liquid zonisamide is rising by the day.
According to IQVIA data, over 150,000 prescriptions of zonisamide are done annually as a treatment for epilepsy. However, the FDA has not approved the liquid form, but it has submitted a new drug application (NDA) for it. Nonetheless, it is optimistic about launching the product in 2021 alongside other neurology-focused liquid product candidates; ET-105 and ET-101.